Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Smoking Termination Opportunity for inPatients (STOP)

7. august 2012 opdateret af: The Queen Elizabeth Hospital

Effectiveness of Inpatient Initiated Varenicline Tartrate for Smoking Cessation, for Smoking Related Illnesses.

The Smoking Termination Opportunity for inPatients, (STOP) project is designed to capture the opportunity that is provided by admission for acute smoking related illness, to assist patients through withdrawal by use of a combination of:

  • the new medication Champix with
  • best practice counselling
  • initiated in an inpatient setting

to achieve:

  • sustained smoking abstinence
  • reduced hospital bed and health service utilisation
  • reduced inpatient smoking and craving prior to discharge

Studieoversigt

Status

Afsluttet

Detaljeret beskrivelse

A national standard in public hospitals for the management of smoking in patients admitted with smoking related acute illnesses is lacking. Where such patients have continued to smoke up until the time of admission, it can be assumed that "primary" prevention has failed.

Once admitted, there is a vastly under-utilised opportunity, by use of a structured and systematic approach, to intervene with a secondary prevention attempt. This takes advantage of the synergy of:

  1. the smoker is a "captive audience" and may be receptive to considering lifestyle factors that have lead to the admission, and
  2. best practice medication and counselling can be initiated prior to discharge. If proven to be cost-effective in our analysis, a systematic roll-out of this secondary prevention initiative would be advocated. ie translation of research into practice.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

392

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • Royal Adelaide Hospital
      • Adelaide, South Australia, Australien, 5011
        • The Queen Elizabeth Hospital
      • Adelaide, South Australia, Australien, 5112
        • Lyell McEwin Health Service

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Smoker of at least 10 cigarettes per day on average over the past 12 months
  • Inpatient with an anticipation admission of at least one day
  • Willingness to quit smoking
  • Aged between 20 and 75 years
  • A plan of discharge to go home
  • Acute hospital admission with cardiovascular, cerebrovascular, peripheral vascular diseases or airways (asthma and/or Chronic Obstructive Pulmonary disease

Exclusion Criteria:

  • Subject preference to use an alternative pharmacotherapy for smoking cessation
  • Respiratory patient being considered for home oxygen
  • Pregnancy
  • Breast feeding
  • Acute or pre-existing severe psychiatric illnesses
  • Past history of psychosis or suicidal ideation
  • Renal impairment with creatinine clearance <30ml/min

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Champix plus counselling
varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service

Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days

1mb b.d. for 70 days (full course 3 months)

Andre navne:
  • Chantix
  • varenicline tartrate
Aktiv komparator: counselling alone
5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
Andre navne:
  • Quitline counselling service

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Smoking abstinence
Tidsramme: one year
Continued smoking abstinence is defined as: less than or equal to no more than 5 cigarettes smoked during the period of 2 weeks to 12 months post enrollment.
one year

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Reduced hospital bed utilisation
Tidsramme: one year
Hospital casemix/DRG data will be collected for the 5 years prior to enrollment and one year post enrollment. This will be supplemented by SA Department of Health data and PBS/MBS data sets of study completion, to monitor admissions at other hospitals and GP visits.
one year
7-day point prevalence
Tidsramme: from 2 weeks to 3 months post enrollment
Defined as no cigarettes for the previous 7 days
from 2 weeks to 3 months post enrollment
Reduction in health care costs
Tidsramme: one year
Reduced health care costs with greater economic value will be relative to other health interventions. Four seperate economic models will be built for vascular diseases: cardiovascular, cerebrovascular and peripheral vascular diseases and airways diseases: asthma and/or chronic obstructive pulmonary disease. Each model will compare outcomes and costs for varenicline and counselling compared to counselling alone, and will incorporate epidemiological data on natural disease progression of smokers and previous smokers from the four disease profiles split by gender if indicated.
one year
Inpatient craving levels
Tidsramme: baseline to end of inpatient stay
Craving scales will be used to assess levels during inpatient stay (pre and post intervention delivery)
baseline to end of inpatient stay
Prevalence of inpatient smoking
Tidsramme: From baseline to end of inpatient stay
Measured by self-report and observation by hospital and study staff prior to discharge.
From baseline to end of inpatient stay

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Brian J Smith, MBBS; FRACP;PhD;Dip Clin Epid, The Queen Elizabeth Hospital

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. maj 2008

Primær færdiggørelse (Faktiske)

1. december 2011

Studieafslutning (Faktiske)

1. december 2011

Datoer for studieregistrering

Først indsendt

10. juni 2010

Først indsendt, der opfyldte QC-kriterier

10. juni 2010

Først opslået (Skøn)

11. juni 2010

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

8. august 2012

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. august 2012

Sidst verificeret

1. april 2010

Mere information

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner